SNPHY (Santen Pharmaceutical Co) Payments of Debt: $0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SNPHY Santen Pharmaceutical Co Ltd SNPHY
85 GF Score
Price $12.53
GF Value $10.45
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Santen Pharmaceutical Co Payments of Debt?

Santen Pharmaceutical Co SNPHY -2.72% 85 Payments of Debt is $0 Mil as of Mar. 2026. GuruFocus rates SNPHY with a GF Score™ of 85/100 and a GF Value™ of $10.45 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Santen Pharmaceutical Co's Payments of Debt for the three months ended in Mar. 2026 was $0 Mil.

Santen Pharmaceutical Co's Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was $0 Mil.

Santen Pharmaceutical Co Payments of Debt Related Terms

Santen Pharmaceutical Co Payments of Debt Historical Data

* Premium members only.

The historical data trend for Santen Pharmaceutical Co's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Santen Pharmaceutical Co Payments of Debt Chart

Santen Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Payments of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -84.41 -14.10 0.00 0.00

Santen Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
SNPHY
85GF Score
Santen Pharmaceutical Co Ltd SNPHY
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Santen Pharmaceutical Co Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of $0 Mil mean?
Santen Pharmaceutical Co (SNPHY) has a Payments of Debt of $0 Mil as of Mar. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Santen Pharmaceutical Co and its competitors.
Is Santen Pharmaceutical Co's Payments of Debt too high?
Santen Pharmaceutical Co's current Payments of Debt is $0 Mil. Overall, Santen Pharmaceutical Co has a GF Score™ of 85/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Santen Pharmaceutical Co's Payments of Debt compare to LLY and JNJ?
Santen Pharmaceutical Co's Payments of Debt of $0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Drug Manufacturers company?
A good Payments of Debt depends on the Drug Manufacturers industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Santen Pharmaceutical Co and its competitors. Santen Pharmaceutical Co's current Payments of Debt is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santen Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Santen Pharmaceutical Co (SNPHY) is currently considered Modestly Overvalued. The stock's GF Value™ is $10.45, compared to a current price of $12.53 — trading 19.9% above its estimated fair value. The current Payments of Debt is $0 Mil. Santen Pharmaceutical Co's overall GF Score™ is 85/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For Santen Pharmaceutical Co (SNPHY), the current Payments of Debt is $0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Santen Pharmaceutical Co (SNPHY) Overvalued in 2026?

Based on GuruFocus' analysis, Santen Pharmaceutical Co stock appears to be overvalued. The current stock price of $12.53 is trading 19.9% above its estimated GF Value™ of $10.45. GuruFocus considers Santen Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for SNPHY:

  • Payments of Debt: $0 Mil
  • GF Value™: $10.45 vs. price of $12.53 (19.9% above fair value)
  • GF Score™: 85/100 with 6 warning signs

No single metric tells the full story. See the SNPHY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Santen Pharmaceutical Co Business Description

Other Exchanges 4536:Japan
Address 4-20 Ofukacho, Grand Front Osaka Tower A, Kita-ku, Osaka Prefecture, Osaka, JPN, 530-8552
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company provides a wide range of prescription and over-the-counter eye care products, including treatments for glaucoma, dry eye, and allergies. It also develops surgical and diagnostic devices related to eye care.
85GF Score

Get the complete analysis for SNPHY

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.53
Price
$10.45
GF Value